Condition: Urologic Neoplasms · Urogenital Neoplasms · Kidney Neoplasms · Sponsor: RenJi Hospital
The aim of this study is to establish and optimize the \[18F\]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.
This description comes directly from the study's public registry record.
Weijun Wei, Ph.D. & M.D. · 15000083153 · wwei@shsmu.edu.cn
Wei Zhai, Ph.D. & M.D. · 18701771959 · jacky_zw2002@hotmail.com
Always discuss trial participation with your own doctor first.
| Renji Hospital, School of Medicine, Shanghai Jiao Tong University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06680089